Overview
Germany is Europe’s largest and most influential medical cannabis market, but it is not a deregulated market. Medical cannabis remains subject to the Medicinal Cannabis Act, medicines law, pharmaceutical quality requirements and professional prescribing obligations. The 2024 Cannabis Act changed the broader legal context, while subsequent policy proposals show that the framework remains politically active.
Legal framework
Medical cannabis is governed separately from non-medical cannabis. The German Medicinal Cannabis Act, commonly referred to as MedCanG, provides the controlled legal framework for cultivation, manufacturing, trade and supply for medical and medical-scientific purposes. Medicinal products and pharmacy preparations also interact with the German Medicinal Products Act and pharmacy law.
The practical consequence is that companies must determine their exact role: cultivator, manufacturer, importer, wholesaler, pharmacy supplier or marketing-authorisation holder. Each role brings different licences and quality obligations. Adult-use reforms do not remove those pharmaceutical responsibilities.
Prescribing and patient access
Medical cannabis may be prescribed by authorised physicians within the applicable professional and legal framework. Products may include authorised cannabis-based medicinal products and pharmacy-dispensed preparations, including flower and extracts. Reimbursement by statutory health insurance follows separate requirements and should not be confused with the legal ability to prescribe.
Commercial forecasting must therefore distinguish prescriptions, reimbursed prescriptions and privately funded supply. A large patient population does not automatically translate into unrestricted product demand because prescriber behaviour, insurer decisions, pharmacy handling and product availability all shape access.
Cultivation, manufacture and import
Companies wishing to cultivate medicinal cannabis require the relevant licence from the Federal Institute for Drugs and Medical Devices. Manufacturing and import activities require appropriate authorisations and GMP compliance where pharmaceutical manufacturing is performed. Imported products must enter through a legally qualified chain with documented oversight, controlled-drug permissions where required and suitable batch certification or release arrangements.
Supplier qualification should examine the complete chain from cultivation and post-harvest processing through testing, packaging, transport and pharmacy supply. Reliance on a single certificate without review of scope, site, activities and current validity is insufficient.
Quality expectations
German authorities and customers generally expect pharmaceutical-grade control. Flower quality should consider identity, cannabinoid content, microbiological quality, foreign matter, pesticides, heavy metals, mycotoxins, water activity or moisture, and stability. Extracts and finished products require additional control of solvents, excipients, homogeneity, container closure and dosage performance.
The European Pharmacopoeia Cannabis flower monograph provides an important official standard. However, compliance with a monograph does not eliminate the need for a product-specific specification, validated or verified methods, stability evidence and deviation management.
Current regulatory risk
Germany’s framework continues to attract policy attention, particularly around prescribing models and remote access. Businesses should avoid treating any proposed amendment as law until the legislative process is complete and the effective date is confirmed. Regulatory intelligence should distinguish enacted law, draft legislation, ministry announcements and professional guidance.
A conservative compliance model assumes that prescription integrity, personal clinical assessment, advertising controls and supply-chain traceability will remain areas of scrutiny. Digital business models should therefore be designed around genuine medical governance rather than minimum-formality access.
Implementation checklist
Before relying on this overview for the German market, confirm current BfArM requirements and CanG provisions directly with the authority, since implementation guidance continues to evolve. Verify GMP import permit requirements if supplying from outside Germany, and confirm prescribing pathway requirements applicable to the specific product and patient population.
Control framework
| Area | Responsible consideration | Typical evidence |
|---|---|---|
| Cultivation | BfArM licence and controlled operations | Licence scope, site controls, security |
| Manufacture/import | Authorisation and GMP compliance | Manufacturing/import licence, GMP certificate |
| Product quality | Pharmacopoeial and product specifications | CoA, methods, stability data |
| Wholesale distribution | GDP and legal supply chain | Wholesale authorisation, qualification records |
| Prescription/reimbursement | Clinical and payer requirements | Prescription route, insurer approval where relevant |
Practical sequence
References and primary guidance
- German Federal Ministry of Health, Frequently asked questions on the Cannabis Act.
- German Federal Ministry of Health, Medicinal Cannabis Act and published amendment materials.
- Federal Institute for Drugs and Medical Devices (BfArM), medicinal cannabis licensing information.
- European Pharmacopoeia monograph 3028: Cannabis flower.
References should be checked against the current consolidated legislation, pharmacopoeial edition and competent-authority guidance before operational use.
Frequently asked questions
Is medical cannabis legal in Germany?
Yes, within the medical framework and subject to prescription, pharmaceutical and licensing requirements.
Did the 2024 Cannabis Act remove medical controls?
No. Medical cannabis remains governed by the separate Medicinal Cannabis Act and applicable medicines law.
Can foreign producers supply Germany?
Potentially, but the manufacturer, importer, product and distribution chain must satisfy applicable German and EU requirements.
Is GMP enough for German market entry?
No. GMP is essential for relevant manufacturing activities but does not replace product, import, wholesale, prescription or reimbursement requirements.
Are proposed prescribing restrictions already law?
Only enacted and effective legislation should be treated as binding; draft amendments must be tracked separately.
Related ECI reading
Educational content only. This page does not constitute medical, legal or regulatory advice.